Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells 15,000 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, November 11th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00.
• On Monday, October 14th, Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04.

CRISPR Therapeutics Stock Down 3.2 %

NASDAQ:CRSP opened at $49.51 on Friday. CRISPR Therapeutics AG has a 52 week low of $43.42 and a 52 week high of $91.10. The stock has a market cap of $4.23 billion, a price-to-earnings ratio of -17.49 and a beta of 1.62. The company’s 50 day moving average price is $48.56 and its 200-day moving average price is $51.53.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period last year, the business posted ($1.41) EPS. As a group, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.14 earnings per share for the current year.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the business. Global Trust Asset Management LLC boosted its holdings in shares of CRISPR Therapeutics by 150.0% during the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares during the last quarter. Larson Financial Group LLC boosted its holdings in CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after purchasing an additional 276 shares during the last quarter. GPS Wealth Strategies Group LLC grew its position in CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after purchasing an additional 307 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in CRISPR Therapeutics during the 2nd quarter valued at $35,000. Finally, Denver PWM LLC bought a new position in shares of CRISPR Therapeutics during the 2nd quarter valued at $45,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CRSP. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Thursday, November 7th. Barclays decreased their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada restated a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $74.94.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.